the highest sensitivity for CAR T-Cell detection in the market
Referred to as “living drugs,” the in vivo pharmacokinetics of CAR T-cells provide indispensable insights into therapeutic responses and potential side effects. Notably, cytokine release syndrome, a common phenomenon in CAR T-cell therapy, is believed to correlate with the expansion of CAR T-cells, emphasizing the pivotal need for early detection of CAR T-cell expansion in vivo. As the first commercially available anti-idiotypic CAR detection antibody provider, we have a wide range of products for various CAR targets, including CD19, BCMA, CD20, and more. Our antibodies are renowned for their specificity and sensitivity.
Our antibody discovery platform ensures a diverse collection of monoclonal antibodies tailored for specific purposes, including PK, ADA/Nab analysis, and long-term (over 5 years) in vivo CAR T-cell monitoring